All In Biotech

Free tool

FAERS Monitor: Tukysa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213411 or its brand name (Tukysa, Tucatinib). Reports on generic versions are filed under their own applications.

Reports

7,107

Serious

4,642

65% of reports

Hospitalization

1,944

Death reported

729

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea1,803
  • fatigue980
  • nausea941
  • vomiting533
  • off label use481
  • death472
  • malignant neoplasm progression455
  • palmar-plantar erythrodysaesthesia syndrome418
  • product dose omission issue377
  • asthenia371
  • decreased appetite323
  • disease progression306
  • metastases to central nervous system305
  • dehydration276
  • neoplasm progression260

Reports by year received

View as table
YearReports
20171
20183
20199
2020797
20211,356
2022974
2023931
20241,684
2025765
2026587

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,052 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
metastases to central nervous systemSignal30571.764.120,690
palmar-plantar erythrodysaesthesia syndromeSignal41854.049.221,332
neoplasm progressionSignal26022.319.85,236
malignant neoplasm progressionSignal45513.212.15,122
diarrhoeaSignal1,8038.38.011,877
disease progressionSignal3067.76.91,774
dehydrationSignal2766.15.51,186
decreased appetiteSignal3234.13.7767
product dose omission issueSignal3773.83.4784
fatigueSignal9803.73.52,027
nauseaSignal9413.53.31,761
vomitingSignal5333.43.1899
astheniaSignal3712.92.6475
off label use4811.61.5120
death4721.61.5117

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.